Abstract
Two subtypes of the mammalian cannabinoid receptor have been identified and successfully cloned since 1990. The CB1 receptor is primarily located in the central nervous system and the CB2 receptor is almost exclusively expressed in cells of the immune system. The CB1 and CB2 receptors are both G-protein coupled receptors and are involved in the inhibition of adenylate cyclase. The CB2 receptor is of particular importance due to its involvement in signal transduction in the immune system, making it a potential target for therapeutic immune intervention. A number of these selective ligands are derivatives of traditional dibenzopyran based cannabinoids. These include the very recently synthesized (2R)- 1-methoxy-3-(2-methylbutyl)-Δ8-THC (JWH-359) which has a 224 fold selectivity for the CB2 receptor, readily comparable to the well known 1-deoxy-3-(1,1-dimethylbutyl)-Δ8-THC (JWH-133) which has 200 fold selectivity for the CB2 receptor. Several 9-hydroxyhexahydrocannabinols have also been synthesized and are found to be selective high affinity ligands for the CB2 receptor. These are 1-deoxy-9β-hydroxy-dimethylhexylhexahydrocannabinol (JWH-361, Ki = 2.7 nM) and 1-deoxy-9β-hydroxy-dimethylpentylhexahydrocannabinol (JWH-300, Ki = 5.3 nM). CB2 selective cannabimimetic indoles include 1-(2,3-dichlorobenzoyl)-2-methyl-3-(2-[1-morpholine]ethyl)-5-methoxyindole (L768242), (R)-3- (2-Iodo-5-nitrobenzoyl)-1-(1-methyl-2-piperidinylmethyl)-1H-indole (AM1241) and 1-propyl-2-methyl-3-(1-naphthoyl) indole (JWH-015), which exhibit significant selectivity for the CB2 receptor coupled with weak affinity for the CB1 receptor. Bristol-Meyer Squibb has produced a phenylalanine derived cannabimimetic indole which possesses high CB2 affinity (Ki = 8 nM) and very low affinity for the CB1 receptor (Ki = 4000 nM). This review will discuss the current advances and recent results in the structure-activity relationships (SAR) of selective ligands for the cannabinoid CB2 receptor.
Keywords: Cannabinoids, structure-activity relationships, CB2 receptor, CB2 selective ligands, aminoalkylindoles
Current Topics in Medicinal Chemistry
Title: Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Volume: 8 Issue: 3
Author(s): John W. Huffman and Karla-Sue C. Marriott
Affiliation:
Keywords: Cannabinoids, structure-activity relationships, CB2 receptor, CB2 selective ligands, aminoalkylindoles
Abstract: Two subtypes of the mammalian cannabinoid receptor have been identified and successfully cloned since 1990. The CB1 receptor is primarily located in the central nervous system and the CB2 receptor is almost exclusively expressed in cells of the immune system. The CB1 and CB2 receptors are both G-protein coupled receptors and are involved in the inhibition of adenylate cyclase. The CB2 receptor is of particular importance due to its involvement in signal transduction in the immune system, making it a potential target for therapeutic immune intervention. A number of these selective ligands are derivatives of traditional dibenzopyran based cannabinoids. These include the very recently synthesized (2R)- 1-methoxy-3-(2-methylbutyl)-Δ8-THC (JWH-359) which has a 224 fold selectivity for the CB2 receptor, readily comparable to the well known 1-deoxy-3-(1,1-dimethylbutyl)-Δ8-THC (JWH-133) which has 200 fold selectivity for the CB2 receptor. Several 9-hydroxyhexahydrocannabinols have also been synthesized and are found to be selective high affinity ligands for the CB2 receptor. These are 1-deoxy-9β-hydroxy-dimethylhexylhexahydrocannabinol (JWH-361, Ki = 2.7 nM) and 1-deoxy-9β-hydroxy-dimethylpentylhexahydrocannabinol (JWH-300, Ki = 5.3 nM). CB2 selective cannabimimetic indoles include 1-(2,3-dichlorobenzoyl)-2-methyl-3-(2-[1-morpholine]ethyl)-5-methoxyindole (L768242), (R)-3- (2-Iodo-5-nitrobenzoyl)-1-(1-methyl-2-piperidinylmethyl)-1H-indole (AM1241) and 1-propyl-2-methyl-3-(1-naphthoyl) indole (JWH-015), which exhibit significant selectivity for the CB2 receptor coupled with weak affinity for the CB1 receptor. Bristol-Meyer Squibb has produced a phenylalanine derived cannabimimetic indole which possesses high CB2 affinity (Ki = 8 nM) and very low affinity for the CB1 receptor (Ki = 4000 nM). This review will discuss the current advances and recent results in the structure-activity relationships (SAR) of selective ligands for the cannabinoid CB2 receptor.
Export Options
About this article
Cite this article as:
Huffman W. John and Marriott C. Karla-Sue, Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor, Current Topics in Medicinal Chemistry 2008; 8 (3) . https://dx.doi.org/10.2174/156802608783498014
DOI https://dx.doi.org/10.2174/156802608783498014 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry Autophagy: A Major Target of Cadmium Nephrotoxicity
Current Chemical Biology Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Recent Progress in Gene Therapy for Parkinson’s Disease
Current Molecular Medicine Subject Index To Volume 12
Current Pharmaceutical Design Recent Advances in Experimental Molecular Therapeutics for Malignant Gliomas
Current Medicinal Chemistry - Anti-Cancer Agents Experimental Therapy for Lung Cancer: Umbilical Cord-Derived Mesenchymal Stem Cell-Mediated Interleukin-24 Delivery
Current Cancer Drug Targets Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme
Current Pharmacogenomics and Personalized Medicine RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Recent Advances in Efficacy of using Doxorubicin Gold Nanoparticles for Chemo-, Radio-, Photothermal, and Photodynamic Therapy
Current Drug Delivery Systems Cytogenomics: Are We Ready Yet?
Current Genomics The Impact of DIDS-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation
Medicinal Chemistry Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design